Acyclovir

證據等級: L5

預測適應症: 10 個

Acyclovir: From Herpes Simplex Virus Infections to Punctate Epithelial Keratoconjunctivitis

One-Sentence Summary

Acyclovir is a first-generation antiviral drug, established for treating herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections including genital herpes, cold sores, chickenpox, and shingles. The TxGNN model predicts it may be effective for Punctate Epithelial Keratoconjunctivitis (PEK), with 0 clinical trials and 2 publications currently supporting this direction — an early-stage mechanistic signal that requires substantial further validation before clinical translation.

Quick Overview

Item	Content
Original Indication	HSV/VZV infections (no local license data available in this dataset)
Predicted New Indication	Punctate Epithelial Keratoconjunctivitis
TxGNN Prediction Score	99.67%
Evidence Level	L4
Market Status	✗ Not Marketed (Taiwan TFDA: 0 registered licenses)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on well-established pharmacology, Acyclovir is a nucleoside analogue prodrug that requires activation by the herpesvirus-encoded thymidine kinase (TK). Once phosphorylated to acyclovir triphosphate by viral TK and host cell kinases, it competitively inhibits viral DNA polymerase — selectively blocking HSV-1, HSV-2, and VZV replication while posing minimal toxicity to host cells. This TK-dependent selectivity is both its strength and its limitation.

Punctate epithelial keratoconjunctivitis (PEK) is a condition characterized by scattered inflammatory lesions on the corneal surface and conjunctiva. HSV-1 and HSV-2 are recognized causative agents of PEK, and since Acyclovir directly targets HSV through the TK-activation pathway, there is a mechanistically coherent rationale for its use in HSV-induced PEK specifically. This is further supported by Acyclovir’s proven efficacy in related HSV ocular conditions — herpetic dendritic keratitis, stromal keratitis, and iridocyclitis — documented in the landmark Herpetic Eye Disease Study (HEDS), suggesting a plausible extension within the same disease family.

However, the prediction carries a critical limitation: PEK is etiologically heterogeneous. Causative agents include adenovirus, microsporidia, toxic drug reactions, and dry eye disease — none of which Acyclovir can address. Neither supporting publication directly validates Acyclovir for PEK: PMID 7825685 describes drug-induced corneal lipidosis in AIDS patients (a distinct pathology), and PMID 21934222 documents microsporidial keratoconjunctivitis caused by a protozoan parasite rather than a virus. The TxGNN model likely captures the broader HSV–keratoconjunctivitis co-occurrence pattern rather than PEK-specific evidence. Pathogen confirmation is a prerequisite before any repurposing attempt.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
7825685	1995	Cohort/Case Series	American Journal of Ophthalmology	Two AIDS patients receiving opportunistic infection treatment developed bilateral ocular surface changes consistent with drug-induced corneal lipidosis; not a direct study of Acyclovir in PEK
21934222	2011	Case Series	Indian Journal of Pathology & Microbiology	Case series of microsporidial keratoconjunctivitis (protozoan etiology) in immunocompetent individuals; illustrates that keratoconjunctivitis frequently has non-HSV causes, underscoring the need for pathogen-specific diagnosis before considering antivirals

Taiwan Market Information

No registered products found. The Taiwan TFDA database records 0 license entries for Acyclovir in this dataset.

Authorization Number	Product Name	Dosage Form	Approved Indication
—	—	—	No records available

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a high TxGNN model score (99.67%), the evidence for Acyclovir in punctate epithelial keratoconjunctivitis is limited to 2 indirect publications (L4) and zero clinical trials. The mechanistic rationale applies only to the HSV-induced subset of PEK — a distinction the current evidence does not confirm — and no clinical data exists to establish efficacy or safety in this specific indication.

To proceed, the following is needed:

Etiology confirmation: Prospective patients must have HSV-confirmed PEK (by PCR or viral culture) before Acyclovir is considered; adenoviral or microsporidial PEK should be excluded
Pilot clinical evidence: A prospective case series or Phase 2 pilot study evaluating topical ophthalmic Acyclovir (or oral Acyclovir/Valacyclovir) in HSV-induced PEK
MOA documentation: Retrieve DrugBank API data to formally document the TK-phosphorylation mechanism and close the existing data gap
Safety data: Obtain Taiwan TFDA package insert to assess contraindications, renal monitoring requirements, and local prescribing restrictions

Note on higher-priority indications: Other TxGNN predictions for Acyclovir carry substantially stronger evidence and should be prioritized for near-term evaluation: Common Wart (Rank 2 — L2, 6 clinical trials including a Phase 2/3 RCT [NCT06261684], 2 direct RCTs in the literature); Post-infectious Neuralgia (Rank 3 — L2, 12 trials via Valacyclovir/Acyclovir on postherpetic neuralgia prevention); and Disease of Orbital Region (Rank 9 — L1, anchored by the Herpetic Eye Disease Study Phase 3 landmark trials). These represent more actionable repurposing opportunities with established biological plausibility.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.